Sygnature wins Bionow Company of the Year

Sygnature Discovery, a leading provider of outsourced drug discovery services, has been named Company of the Year at the Bionow Annual Awards 2020. The goal of these awards is to highlight the outstanding success and achievements of those who worked tirelessly over the past year, and recognise the incredible progress that has been made during this challenging period. The Company of the Year category included a broad criteria that looked at the company’s strategy, expanded services, acquisitions, investment in training, company growth and future plans.

In the last year, Sygnature has been able to continue its fantastic journey of growth and success. By adapting and supporting its scientists, Sygnature has been able to remain fully operational in a safe and sustainable manner throughout 2020 and into 2021. The acquisition of Alderley Oncology and XenoGesis have also been important steps in expanding Sygnature’s capabilities and fulfilling the company’s mission of delivering truly integrated drug discovery solutions.

“It is fantastic for Sygnature to be recognised by Bionow in the Life Sciences industry. I believe it acknowledges the sustained contribution of our staff to delivering innovative research to the pharmaceutical industry.”
Dr Paul Overton, Chief Commercial Officer at Sygnature Discovery